Biotech Values

[DewDiligence]

Follow-up quiz on BMY’s all-oral HCV combo:

The following trial combines two oral HCV drugs from Bristol-Myers: BMS-650032, a protease/NS3 inhibitor, and BMS-790052, an NS5A inhibitor:

http://clinicaltrials.gov/ct2/show/NCT01012895

This study was the answer to a recent quiz solved by ‘julescat’ (#msg-44002107, #msg-44000662). It’s the only HCV study (as far as I know) where two oral agents—of which neither has completed even a phase-2a study—are being combined in a regimen that does not include interferon or ribavirin.

New quiz question: What other consequential feature of this trial is a first in the HCV arena?